Literature DB >> 15275127

Modulating ongoing Th2-cell responses in experimental leishmaniasis.

G S Nabors1.   

Abstract

Dramatically polarized T helper (Th)-cell responses are seen in experimental murine infections with Leishmania major. Resistant mice develop a Th1-cell type response and heal the primary lesion, while susceptible mice develop non-protective Th2-cell responses, and the disease eventually proves fatal. Deservedly, much effort has gone into determining factors that influence the development of these T-cell subsets early in infection; however, little is known about how the polarity of established responses can be permanently modified. In this article, Gary Nabors reviews his findings on modifying ongoing Th2-cell responses in susceptible mice, and discusses therapies that have proven effective involving reducing the level of infection using a conventional antileishmanial drug, combined with agents that push the response towards the Th1 pole.

Entities:  

Year:  1997        PMID: 15275127     DOI: 10.1016/s0169-4758(96)10078-8

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  5 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

4.  Essential role of platelet-activating factor in control of Leishmania (Leishmania) amazonensis infection.

Authors:  M V Lonardoni; M Russo; S Jancar
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

5.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.